NLRP3 and diabetic kidney disease: Although in-depth studies of this intracellular signaling pathway in the DKD state are lacking, it has been demonstrated that FOXO1 can suppress NLRP3 inflammasome activation by reducing the TXNIP level in patients with diabetic atherosclerosis and diabetic liver (41, 42).